Today, "Forbes" published a story detailing a "milestone moment" in the history of LRRK2 and the linchpin role of The Michael J. Foundation in ushering this promising genetic target forward.
Read more about how LRRK2 drugs nearly stalled, the Foundation's role in uniting the field toward a solution and the recent first-in-human trial results from Denali Therapeutics, which could lead to breakthroughs for Parkinson's disease.
No hay comentarios:
Publicar un comentario